Posted by Michael Wonder on 31 Mar 2022
Chugai obtains regulatory approval for Perjeta and Herceptin for additional indication of HER2 positive colorectal cancer
28 March 2022 - Combination therapy of Perjeta and Herceptin obtained regulatory approval for advanced or recurrent HER2 positive colon cancer or rectal cancer not amenable to curative resection that has progressed after cancer chemotherapy.
Chugai Pharmaceutical announced that it obtained regulatory approval from the MHLW for the anti-HER2 humanised monoclonal antibodies, Perjeta and Herceptin for the additional indication of advanced or recurrent HER2 positive colon cancer or rectal cancer not amenable to curative resection that has progressed after cancer chemotherapy.
